Search

everythinglearnresearchcommunity

for

Search:↓

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.

Exosome stem cell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

User tried finasteride and minoxidil for hair loss, now considering exosomes injections. Will update on results after appointment.

User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.

Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.

The conversation discusses using Botox to treat male pattern baldness, suggesting it may promote hair growth by increasing scalp blood flow and oxygen, reducing dihydrotestosterone levels. The user wonders why this treatment is not widely discussed or if it has been discredited.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The user experienced initial success with finasteride and topical minoxidil, but hair loss returned, leading to changes in treatment including dutasteride, oral minoxidil, and supplements. Despite increasing minoxidil dosage, hair loss persisted, prompting consideration of injectable treatments.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.

A user tried various treatments for hair loss, including Metanx, Nizoral, hair transplants, and scalp massages, with limited success. They recently experimented with Botox injections in the scalp, which significantly reduced scalp itch and shedding, though it's too early to see regrowth.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Topical Dutasteride 0.05% twice a week and Dutasteride Mesotherapy 0.01% once a week showed noticeable improvement in hair loss over six months without side effects. The user plans to add Minoxidil tablets 2.5mg daily to their treatment.

The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The user treated hair loss for one year using low dose topical finasteride, minoxidil, RU58841, ketoconazole shampoo, dermastamping, Botox injections, and supplements. They saw a subtle improvement in their hair loss.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The user shared 9-month results using a 4-in-1 spray containing finasteride, minoxidil, ketoconazole, and biotin, along with lifestyle changes like jogging, quitting smoking, and using collagen supplements. They also incorporated dermastamping, dermarolling, and various oils into their routine, reporting positive hair regrowth.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.